Mr Doug Treco

KANDO id: 40969

Bio

Doug joined Morgenthaler Ventures in early 2008 as an Entrepreneur-in-Residence in the Life Science Team. Shortly after joining the team, he took on the responsibilities of CEO of Ra Pharmaceuticals, Inc., a drug discovery start-up being incubated in Morgenthaler’s Boston office. Doug received a Ph.D. degree in Biochemistry and Molecular Biology from SUNY Stony Brook and performed post-doctoral studies at the Salk Institute and Massachusetts General Hospital. In 1988 he co-founded Transkaryotic Therapies, Inc. (acquired in 2005 by Shire plc), a multi-platform biopharmaceutical company developing protein and gene therapy products. He has authored numerous peer-reviewed publications and holds 35 US and European patents in the areas of protein production, gene mapping and gene therapy.


Career


Morgenthaler Management Partners

One of the oldest private equity investment firms in the US investing through both venture capital and leverage buyout transactions.
Email: [email protected]

Education